BioLife Solutions chief quality and operations officer sells $8,249 in stock

Karen A. Foster, the Chief Quality and Operations Officer at BioLife Solutions Inc. (NASDAQ:BLFS), a company currently valued at $1.17 billion, sold a portion of her holdings in the company. According to InvestingPro data, the company maintains strong liquidity with a current ratio of 4.54x, indicating robust financial health. According to a recent SEC filing, Foster sold 324 shares of BioLife Solutions common stock on March 3, 2025, at a price of $25.46 per share, totaling approximately $8,249. The stock has since moved to $26.25, showing characteristic volatility that InvestingPro analysts have identified as a key feature of this investment. Following this transaction, Foster retains ownership of 156,243 shares in the company. This sale was conducted under a pre-established Rule 10b5-1 trading plan, designed to cover tax withholding obligations related to the vesting of restricted stock. Get access to more detailed insider trading analysis and 6 additional key ProTips with InvestingPro’s comprehensive research reports.

In other recent news, BioLife Solutions reported impressive fourth-quarter financial results, surpassing expectations with revenues of $22.7 million, slightly higher than Benchmark’s projection of $22.0 million. The company posted a narrower-than-expected Q4 loss of -$0.04 per share, outperforming analyst estimates of -$0.08 per share. A significant driver of this performance was the Cell Processing segment, which saw revenue increase by 37% year-over-year to $20.3 million. This marks the fifth consecutive quarter of revenue growth for the segment, highlighting its strong momentum. Benchmark maintained a Buy rating for BioLife Solutions, with a price target of $30, reflecting confidence in the company’s growth prospects. Looking ahead, BioLife Solutions provided optimistic guidance, forecasting 2025 revenue between $95.5 million and $99 million, representing a 16-20% increase over 2024. The company also expects Cell Processing revenue to grow by 18-21% to $86.5-$89 million. BioLife’s biopreservation media is currently embedded in 17 approved cell and gene therapies, with additional approvals anticipated in the coming year. These developments emphasize BioLife’s strengthened position in the cell and gene therapy market.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.